PV-305

PV-305 is an investigational ophthalmic drug developed as a topical formulation for the treatment of infectious keratitis and other serious ocular conditions. It is a formulation of PV-10, which itself consists solely of Provectus’s pharmaceutical-grade rose bengal sodium (RBS) in saline solution. The mechanism involves photodynamic antimicrobial therapy (RB-PDAT), where PV-305 is administered topically to the eye followed by illumination with green light, resulting in a multi-modal antimicrobial effect against bacteria, fungi, and parasites—including multidrug-resistant organisms. The therapy aims to resolve infections non-invasively and avoid surgical intervention. PV-305 is being advanced by VisiRose, a spinoff from Provectus Biopharmaceuticals in collaboration with the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute (University of Miami). As of early 2025, it is undergoing regulatory steps toward clinical trials for infectious keratitis[1][2][3][5][7].

Other names

rose bengal sodium